Status:

ACTIVE_NOT_RECRUITING

Examining the Effect of a Digital MD for Cognitive and Musical Training + Reduced Conventional SOC on the Reading and Writing Skills of Pediatric Participants With a Specific Learning Disability With Reading and/or Written Expression Deficit vs a Control Group Receiving Conventional SOC.

Lead Sponsor:

Poppins

Collaborating Sponsors:

Lindus Health

Conditions:

Learning Disorder, Specific

Learning Disability

Eligibility:

All Genders

7-11 years

Phase:

NA

Brief Summary

Poppins-02 is a multicentric randomized non-inferiority study examining the effect of the digital medical device Poppins Clinical for cognitive and musical training in addition to bi-monthly speech an...

Detailed Description

The study is a multicentric randomized non-inferiority clinical trial that has the aim to evaluate the impact of the digital medical device Poppins Clinical in addition to reduced speech and reading t...

Eligibility Criteria

Inclusion

  • Diagnosis of SLD with reading deficit, based on a speech-language assessment. SLD with reading deficit is defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR, 2022). The speech-language assessment should consist of at least three reading and/or transcription tests with a SD (standard deviation) of at least - 1.4 or a result below the 20th percentile or two reading and/or transcription tests with a SD of at least - 2 SD or a results below the 10th percentile;
  • Subject aged between 7 and 11, enrolled from CE1 to CM2;
  • Subject receiving speech and reading therapy for less than 2 years, receiving speech and reading therapy for written language for less than 2 years, with a maximum treatment frequency of one session per week, either for at least 3 months for children followed for more than 3 months, or for the duration of the treatment for children followed for less than 3 months.;
  • French mother tongue or French bilingualism at home and more than 3 years schooling in France;
  • Tablet or smartphone available at home;
  • Subject affiliated to the French National Insurance (Sécurité Sociale);
  • Subject and parental/legal guardians consent to participate, and commitment to follow the protocol.

Exclusion

  • Subject has previously used Poppins Clinical or a previous version (Mila-Learn);
  • Unstabilized chronic illness (at investigator's discretion);
  • Participants with autism spectrum disorders or documented intellectual disabilities;
  • Vision or Hearing difficulties preventing the use of the tablet or smartphone;
  • Any condition that, in the opinion of the investigator, may prevent the patient from participating in the trial
  • Participant actively participating in an interventional study that may affect results.
  • Concurrent participation of any other family member in the same clinical trial

Key Trial Info

Start Date :

December 20 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2026

Estimated Enrollment :

306 Patients enrolled

Trial Details

Trial ID

NCT06592911

Start Date

December 20 2024

End Date

January 1 2026

Last Update

September 22 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Hôpital Pitié-Salpêtrière, Paris, Paris 75013

Paris, France, 75013

2

Hôpital Henri Laborit Poitiers, 86000

Poitiers, France, 86000